Cartalax – Powder

Description

Cartalax – Research Peptide | 20 mg

Cartalax is a synthetic short peptide composed of three amino acids: Alanine–Glutamic Acid–Aspartic Acid (Ala–Glu–Asp). It belongs to the class of tissue-specific peptide bioregulators developed as part of the Cytogen series in Russia. Cartalax is designed to modulate gene expression involved in the maintenance and repair of cartilage and connective tissue, and is being studied for potential use in joint degeneration and inflammatory conditions.

Scientific Background:

Cartalax and similar short peptides are theorized to act by binding to DNA or nuclear receptors, influencing the transcription of genes related to tissue repair and protein synthesis. Research from the St. Petersburg Institute of Bioregulation and Gerontology suggests that these peptides may normalize cell function in specific tissues, especially chondrocytes (cartilage-forming cells) [Khavinson et al., Biogerontology, 2016].

Although formal clinical trials outside Russia are limited, Cartalax is used in preclinical research for:

• Cartilage regeneration in osteoarthritic models
• Anti-inflammatory effects in degenerative joint conditions
• Enhancement of tissue-specific homeostasis via epigenetic modulation

Potential Research Applications:

• Joint and cartilage regeneration
• Inflammation reduction in synovial tissues
• Improved chondrocyte gene expression
• Adjuvant use with other peptides (may increase cellular peptide uptake)

Specifications:

• CAS: Not assigned
• Molar Mass: 430.17 g/mol
• Sequence: Ala–Glu–Asp
• Purity: ≥ 99% (HPLC)
• Form: Lyophilized powder
• Quantity: 20 mg per vial
• Storage:
  • Short-term: Refrigerate (2–8 °C), tightly sealed and protected from moisture, heat, and light
  • Long-term: Store at –20 °C or lower